The better-than-expected loss per share could be seen positively by investors, suggesting some operational efficiency or cost control. However, the miss on sales estimates could raise concerns about revenue growth and market demand for Femasys's products. The mixed results make the short-term impact on the stock price uncertain, hence a neutral score.